SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Amedisys Inc – ‘10-K’ for 12/31/19 – ‘EX-31.2’

On:  Wednesday, 2/19/20, at 9:39am ET   ·   For:  12/31/19   ·   Accession #:  896262-20-6   ·   File #:  0-24260

Previous ‘10-K’:  ‘10-K’ on 2/28/19 for 12/31/18   ·   Next:  ‘10-K’ on 2/25/21 for 12/31/20   ·   Latest:  ‘10-K/A’ on 4/26/24 for 12/31/23   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/19/20  Amedisys Inc                      10-K       12/31/19  111:14M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.96M 
 2: EX-4.2      Instrument Defining the Rights of Security Holders  HTML     39K 
 4: EX-10.20    Material Contract                                   HTML    126K 
 5: EX-10.26    Material Contract                                   HTML    211K 
 3: EX-10.3     Material Contract                                   HTML    117K 
 6: EX-21.1     Subsidiaries List                                   HTML     46K 
 7: EX-23.1     Consent of Experts or Counsel                       HTML     32K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     31K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     31K 
25: R1          Cover Page                                          HTML     91K 
75: R2          Consolidated Balance Sheets                         HTML    131K 
94: R3          Consolidated Balance Sheets (Parenthetical)         HTML     58K 
55: R4          Consolidated Statements of Operations               HTML    111K 
28: R5          Consolidated Statements of Comprehensive Income     HTML     51K 
                (Loss)                                                           
77: R6          Consolidated Statements of Stockholders' Equity     HTML    106K 
95: R7          Consolidated Statements of Cash Flows               HTML    155K 
59: R8          Nature of Operations, Consolidation and             HTML     53K 
                Presentation of Financial Statements                             
23: R9          Summary of Significant Accounting Policies          HTML    149K 
61: R10         Acquisitions                                        HTML     68K 
30: R11         Goodwill and Other Intangible Assets, Net           HTML     94K 
88: R12         Details of Certain Balance Sheet Accounts           HTML     74K 
102: R13         Leases Leases                                       HTML     88K  
62: R14         Long-Term Obligations                               HTML     90K 
31: R15         Income Taxes                                        HTML    144K 
89: R16         Capital Stock and Share-Based Compensation          HTML    138K 
103: R17         Commitments and Contingencies                       HTML     77K  
63: R18         Employee Benefit Plans                              HTML     35K 
29: R19         Share Repurchase                                    HTML     36K 
67: R20         Exit and Restructuring Activities                   HTML     33K 
104: R21         Segment Information                                 HTML    120K  
42: R22         Unaudited Summarized Quarterly Financial            HTML     68K 
                Information                                                      
34: R23         Related Party Transactions                          HTML     35K 
68: R24         Subsequent Events                                   HTML     32K 
105: R25         Summary of Significant Accounting Policies          HTML    199K  
                (Policies)                                                       
43: R26         Summary of Significant Accounting Policies          HTML    109K 
                (Tables)                                                         
35: R27         Acquisitions (Tables)                               HTML     57K 
66: R28         Goodwill and Other Intangible Assets, Net (Tables)  HTML     95K 
106: R29         Details of Certain Balance Sheet Accounts (Tables)  HTML    209K  
101: R30         Leases Leases (Tables)                              HTML     92K  
86: R31         Long-Term Obligations (Tables)                      HTML     80K 
33: R32         Income Taxes (Tables)                               HTML    140K 
65: R33         Capital Stock and Share-Based Compensation          HTML    123K 
                (Tables)                                                         
100: R34         Commitments and Contingencies (Tables)              HTML     42K  
85: R35         Segment Information (Tables)                        HTML    120K 
32: R36         Unaudited Summarized Quarterly Financial            HTML     68K 
                Information (Tables)                                             
64: R37         NATURE OF OPERATIONS, CONSOLIDATION AND             HTML     63K 
                PRESENTATION OF FINANCIAL STATEMENTS - Narrative                 
                (Details)                                                        
99: R38         NATURE OF OPERATIONS, CONSOLIDATION AND             HTML     52K 
                PRESENTATION OF FINANCIAL STATEMENTS - Recently                  
                Issued Accounting Pronouncements (Details)                       
87: R39         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     74K 
                Revenue Recognition Narrative (Details)                          
111: R40         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     47K  
                Revenue Recognition by Payor Class (Details)                     
72: R41         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash   HTML     44K 
                and Cash Equivalents (Details)                                   
37: R42         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     54K 
                Patient Accounts Receivable Narrative (Details)                  
45: R43         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     53K 
                Additional Information Narrative (Details)                       
110: R44         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     50K  
                Estimated Useful Lives of Property and Equipment                 
                (Details)                                                        
71: R45         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     49K 
                Balances Related to Property and Equipment                       
                (Details)                                                        
36: R46         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     35K 
                Goodwill and Intangibles (Details)                               
44: R47         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Debt   HTML     37K 
                Issuance Costs (Details)                                         
109: R48         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     40K  
                Financial Instruments Where Carrying Value and                   
                Fair Value Differ (Details)                                      
73: R49         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     45K 
                Weighted Average Shares Outstanding (Details)                    
83: R50         ACQUISITIONS - Narrative (Details)                  HTML    182K 
96: R51         ACQUISITIONS - Pro Forma Condensed Consolidated     HTML     45K 
                Statement of Income (Details)                                    
50: R52         GOODWILL AND OTHER INTANGIBLE ASSETS, NET -         HTML     48K 
                Activity Related to Goodwill (Details)                           
17: R53         GOODWILL AND OTHER INTANGIBLE ASSETS, NET -         HTML     70K 
                Activity Related to Other Intangible Assets, Net                 
                (Details)                                                        
84: R54         GOODWILL AND OTHER INTANGIBLE ASSETS, NET -         HTML     45K 
                Estimated Future Amortization Expense (Details)                  
97: R55         DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS -         HTML     98K 
                Balances (Details)                                               
51: R56         Leases (Details)                                    HTML     44K 
18: R57         Leases Lease Cost (Details)                         HTML     51K 
82: R58         LEASES Operating Lease (Details)                    HTML     38K 
98: R59         LEASES Finance Lease (Details)                      HTML     42K 
46: R60         LEASES Supplemental Cash Flow Information           HTML     44K 
                (Details)                                                        
40: R61         LEASES Weighted Average Remaining Term and          HTML     40K 
                Discount Rate (Details)                                          
69: R62         LEASES Maturities (Details)                         HTML     69K 
107: R63         LONG-TERM OBLIGATIONS - Summary of Long-Term Debt   HTML     56K  
                (Details)                                                        
48: R64         LONG-TERM OBLIGATIONS - Summary of Long-Term Debt   HTML     47K 
                Additional Information (Details)                                 
41: R65         LONG-TERM OBLIGATIONS - Maturities of Debt          HTML     49K 
                (Details)                                                        
70: R66         LONG-TERM OBLIGATIONS - Fees and Rates Under        HTML     66K 
                Credit Facilities (Details)                                      
108: R67         LONG-TERM OBLIGATIONS - Narrative (Details)         HTML    144K  
49: R68         INCOME TAXES - Narrative (Details)                  HTML     70K 
38: R69         INCOME TAXES - Components of Tax Provision by       HTML     55K 
                Jurisdiction (Details)                                           
24: R70         INCOME TAXES - Income Tax Expense Allocation        HTML     42K 
                (Details)                                                        
60: R71         INCOME TAXES - Reconciliation of Effective Tax      HTML     49K 
                Rate (Details)                                                   
93: R72         INCOME TAXES - Components of Deferred Tax Assets    HTML     86K 
                (Liabilities) (Details)                                          
81: R73         INCOME TAXES - Reconciliation of Unrecognized Tax   HTML     48K 
                Benefits (Details)                                               
19: R74         CAPITAL STOCK AND SHARE-BASED COMPENSATION -        HTML    127K 
                Narrative (Details)                                              
56: R75         CAPITAL STOCK AND SHARE-BASED COMPENSATION -        HTML     40K 
                Employee Stock Purchase Plan Purchases (Details)                 
90: R76         CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock  HTML     53K 
                Option Valuation Assumptions (Details)                           
78: R77         CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock  HTML     67K 
                Option Activity (Details)                                        
27: R78         CAPITAL STOCK AND SHARE-BASED COMPENSATION -        HTML     49K 
                Non-Vested Stock Option Activity (Details)                       
53: R79         CAPITAL STOCK AND SHARE-BASED COMPENSATION -        HTML     57K 
                Non-Vested Stock Activity (Details)                              
22: R80         CAPITAL STOCK AND SHARE-BASED COMPENSATION -        HTML     65K 
                Non-Vested Stock Units Activity (Details)                        
58: R81         COMMITMENTS AND CONTINGENCIES - Narrative           HTML    156K 
                (Details)                                                        
92: R82         COMMITMENTS AND CONTINGENCIES - Insurance Programs  HTML     40K 
                (Details)                                                        
80: R83         EMPLOYEE BENEFIT PLANS - Narrative (Details)        HTML     38K 
20: R84         SHARE REPURCHASE - Narrative (Details)              HTML     48K 
57: R85         EXIT AND RESTRUCTURING ACTIVITIES - Narrative       HTML     52K 
                (Details)                                                        
91: R86         SEGMENT INFORMATION - Narrative (Details)           HTML     31K 
79: R87         SEGMENT INFORMATION - Operating Income of           HTML     86K 
                Reportable Segments (Details)                                    
26: R88         UNAUDITED SUMMARIZED QUARTERLY FINANCIAL            HTML     51K 
                INFORMATION Operating Activity (Details)                         
52: R89         RELATED PARTY TRANSACTIONS - Narrative (Details)    HTML     54K 
47: R90         SUBSEQUENT EVENTS Narrative (Details)               HTML     37K 
39: XML         IDEA XML File -- Filing Summary                      XML    198K 
76: XML         XBRL Instance -- amed-20193112x10xk_htm              XML   3.25M 
54: EXCEL       IDEA Workbook of Financial Reports                  XLSX    136K 
13: EX-101.CAL  XBRL Calculations -- amed-20191231_cal               XML    324K 
14: EX-101.DEF  XBRL Definitions -- amed-20191231_def                XML   1.05M 
15: EX-101.LAB  XBRL Labels -- amed-20191231_lab                     XML   2.80M 
16: EX-101.PRE  XBRL Presentations -- amed-20191231_pre              XML   1.68M 
12: EX-101.SCH  XBRL Schema -- amed-20191231                         XSD    302K 
74: JSON        XBRL Instance as JSON Data -- MetaLinks              543±   815K 
21: ZIP         XBRL Zipped Folder -- 0000896262-20-000006-xbrl      Zip    580K 


‘EX-31.2’   —   Certification — §302 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  


Exhibit 31.2
CERTIFICATION
I, Scott G. Ginn, certify that:
1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2019, of Amedisys, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 19, 2020
Chief Financial Officer
(Principal Financial Officer)



Dates Referenced Herein

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/19/20None on these Dates
For Period end:12/31/19
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/26/24  Amedisys Inc.                     10-K/A     12/31/23   14:1.3M                                   Donnelley … Solutions/FA
 2/22/24  Amedisys Inc.                     10-K       12/31/23  112:14M
 2/16/23  Amedisys Inc.                     10-K       12/31/22  108:15M
 2/24/22  Amedisys Inc.                     10-K       12/31/21  106:14M
 2/25/21  Amedisys Inc.                     10-K       12/31/20  107:14M
Top
Filing Submission 0000896262-20-000006   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 8, 12:50:29.1am ET